Zymeworks stock fell 3.12 percent after Theravance deal closes

Published on 10/04/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zymeworks stock closed at USD 25.15 on October 2 after the Theravance deal. The company set 2026 revenue guidance at USD 278 million-292 million.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks stock (ISIN US98985Y1082) closed at USD 25.15 on Nasdaq on October 2, 2026, down 3.12 percent from the previous close. The company completed its Theravance Biopharma acquisition and issued 2026 guidance for USD 278 million-292 million of revenue on September 28.

Theravance adds recurring cash flow

According to Zymeworks, the transaction adds YUPELRI profit-sharing rights, royalties, a commercial organization and research assets to the biotechnology company. YUPELRI sales totaled USD 133.1 million in the first half of 2026 and generated USD 38.4 million of collaboration revenue for Theravance, the release said.

The company also reported 25 percent year-over-year growth in YUPELRI hospital sales in Q2 2026. Zymeworks is entitled to 35 percent of US net profits from YUPELRI, while 75 percent of its profit-share cash flows will service a USD 350 million non-recourse note from OMERS until repayment.

Guidance points to a wider base

The updated 2026 outlook includes adjusted EBITDA of USD 114 million-128 million, excluding future transactions, according to Zymeworks on September 28, 2026. The company used USD 217.5 million of existing cash resources to finance part of the purchase price after applying cash acquired from Theravance.

The acquisition changes the revenue mix from a primarily research-driven model toward commercial, royalty and collaboration cash flows. The company also expects a potential USD 100 million TRELEGY ELLIPTA milestone payment in Q1 2027 if the relevant sales conditions are met, making execution of the acquired assets a key financial variable.

Analyst targets remain above Nasdaq price

Investing.com lists a Strong Buy consensus for Zymeworks based on 13 analysts as of September 18, 2026. The average 12-month target is USD 41.23, with a low of USD 32.00 and a high of USD 60.00, according to Investing.com; the average target lies 63.9 percent above the October 2 price.

B. Riley rated the stock Buy with a USD 44 price target in coverage published September 25, 2026, while the firm modeled Q3 2026 revenue at USD 99.8 million against consensus of USD 99.1 million, according to Investing.com.

Zymeworks stock stays below yearly high

Zymeworks stock closed at USD 25.15 on October 2, 2026, with a session range of USD 25.04-26.37 and a 52-week range of USD 16.00-31.34. Its market capitalization was USD 1.8 billion and volume reached 844,443 shares on Nasdaq.